OMIT is administered via a specially formulated toothpaste that incorporates and stabilizes allergens (food proteins). Intrommune’s technology has been used in over 1,000 patients suffering from respiratory allergies and Intrommune has begun its clinical proof-of-concept study for peanut allergies to scientifically validate the OMIT toothpaste platform approach. Published research demonstrates safety and adherence advantages over other allergy immunotherapies. Intrommune strives to transform lives by meeting the significant health care need for effective food allergy treatments through the oral mucosal immunotherapy (OMIT) platform and lead product INT301.

Intrommune’s mission is to develop safe and effective options for food allergy sufferers so they and their loved ones can live their lives without fear.

Intrommune Therapeutics is a biotechnology company developing patient-friendly therapies for the treatment of food allergies. The company’s oral mucosal immunotherapy (OMIT) platform is based on the well-accepted principles of allergy immunotherapy. Immunotherapeutic agents are regularly administered to areas of the oral cavity with the highest likelihood of decreasing allergy symptoms, gradually desensitizing the immune system to specific foods.